Want to see ZVSA full AI Analyst Report?
ZVSA Stock Chart & Stats
$0.13
-$0.05(-3.87%)
At close: 4:00 PM EST
$0.13
-$0.05(-3.87%)
Day’s Range― - ―
52-Week Range$0.10 - $0.30
Previous CloseN/A
Volume38.43K
Average Volume (3M)51.59K
Market Cap
$939.13K
Enterprise Value$2.52
Total Cash (Recent Filing)$302.66M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.32
Shares Outstanding8,095,921
10 Day Avg. Volume65,792
30 Day Avg. Volume51,592
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-156.26
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Renal/metabolic PipelineZyVersa’s concentrated scientific focus on kidney and metabolic diseases and on inflammatory/fibrotic mechanisms creates a durable, specialist R&D profile. This narrows development scope, builds domain expertise, and targets chronic unmet needs where successful clinical outcomes can generate sustained commercial value.
Management Cost DisciplineSenior management’s voluntary pay reductions and active cost-cutting signal alignment with shareholders and pragmatic stewardship. Durable cost discipline can extend operational runway, reduce fixed burn, and improve negotiability with partners or acquirers during prolonged clinical development cycles.
Strategic Transaction FlexibilityPursuing broad strategic alternatives (asset sales, restructuring or a full sale) gives the company durable pathways to address capital shortfalls. These options can materially alter capital structure, unlock asset value, and provide non-dilutive liquidity or a faster route to commercialization if clinical assets attract buyers.
Bears Say
Severe Cash BurnOperating and free cash flow are sharply negative and deteriorating, implying the company will need material external financing in the near term. This structural cash consumption elevates dilution risk, compresses strategic options, and threatens the ability to advance clinical programs without partners or capital injections.
Deeply Negative Equity & Rising DebtA heavily negative equity position combined with rising debt (1.2B vs 742M assets in TTM) materially constrains financial flexibility. This stressed capital structure increases insolvency and refinancing risk, reduces bargaining power with counterparties, and can impair ability to execute long-term R&D strategies.
Pre-commercial Profile, No RevenueThe company reports zero revenue across all provided periods while incurring large, persistent losses. Dependence on financing rather than product cash flow makes long-term viability contingent on successful clinical milestones or third-party funding, raising structural execution and funding risks.
ZyVersa Therapeutics News
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.10 and its highest was $0.30 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $939.13K.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 27 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Overvalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 8,095,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.556%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―